Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy

• Published in: Cancers Vol. 14; no. 1; p. 239
• Main Authors: Mattila, Kalle E, Vainio, Paula, Jaakkola, Panu M
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 04-01-2022; MDPI
• Subjects: Adjuvant therapy; Algorithms; Biomarkers; Blood clots; Blood vessels; Cancer therapies; Clear cell-type renal cell carcinoma; Clinical trials; Gene expression; Kidney cancer; Kidneys; Lymphatic system; Medical prognosis; Metastases; Metastasis; Nephrectomy; Patients; Placebos; Prediction models; Review; Risk assessment; Risk groups; Surgery; Surveillance; Tumors; Veins & arteries; adjuvant therapy; clear cell renal cell carcinoma; prediction model; prognostic factor; biomarker
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14010239

Approximately 20% of patients with renal cell carcinoma (RCC) present with primarily metastatic disease and over 30% of patients with localized RCC will develop distant metastases later, after complete resection of the primary tumor. Accurate postoperative prognostic models are essential for designing personalized surveillance programs, as well as for designing adjuvant therapy and trials. Several clinical and histopathological prognostic factors have been identified and adopted into prognostic algorithms to assess the individual risk for disease recurrence after radical or partial nephrectomy. However, the prediction accuracy of current prognostic models has been studied in retrospective patient cohorts and the optimal set of prognostic features remains unclear. In addition to traditional histopathological prognostic factors, novel biomarkers, such as gene expression profiles and circulating tumor DNA, are extensively studied to supplement existing prognostic algorithms to improve their prediction accuracy. Here, we aim to give an overview of existing prognostic features and prediction models for localized postoperative clear cell RCC and discuss their role in the adjuvant therapy trials. The results of ongoing placebo-controlled adjuvant therapy trials may elucidate prognostic factors and biomarkers that help to define patients at high risk for disease recurrence.